RBM 39 targeting therapeutic (Recursion Pharmaceuticals)

SEED Therapeutics presented two breakthrough research programs at AACR 2025, showcasing advances in targeted protein degradation technology for cancer treatment.

Recursion has initiated the EXCELERIZE Phase 1 clinical trial of REC-3565, a selective MALT1 inhibitor designed to treat relapsed or refractory B-cell lymphomas.

BeyondSpring's Plinabulin demonstrated statistically significant survival benefits in second and third-line non-small cell lung cancer (EGFR wild-type) patients, with results published in The Lancet Respiratory Medicine.

SEED Therapeutics has received both Rare Pediatric Disease and Orphan Drug designations from the FDA for their molecular glue ST-01156, which targets RBM39 in solid tumors. The company is preparing for an IND filing in early 2025, with the potential to receive a priority review voucher upon approval.

Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.